A share price of Alnylam Pharmaceuticals Inc [ALNY] is currently trading at $155.90, down -0.09%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ALNY shares have gain 3.22% over the last week, with a monthly amount glided 4.06%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 7, April 2024, Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension. In a post published today on Yahoo Finance, – Study Met Primary Endpoint Demonstrating Clinically Significant Additive Reductions in Ambulatory Systolic Blood Pressure of Up to 12.1 mmHg Across Three Independent Study Cohorts at Month 3 –.
From an analyst’s perspective:
Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] stock has seen the most recent analyst activity on February 16, 2024, when Goldman downgraded its rating to a Neutral but kept the price target unchanged to $173 for it. On December 08, 2023, Wells Fargo initiated with a Equal Weight rating and assigned a price target of $171 on the stock. Wells Fargo started tracking the stock assigning a Equal Weight rating. Oppenheimer downgraded its rating to a Perform. Raymond James started tracking with a Outperform rating for this stock on September 29, 2023, and assigned it a price target of $208. In a note dated May 05, 2023, BMO Capital Markets upgraded an Outperform rating on this stock and boosted its target price from $200 to $250.
Alnylam Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $143.52 and $218.88. Currently, Wall Street analysts expect the stock to reach $216.12 within the next 12 months. Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] shares were valued at $155.90 at the most recent close of the market. An investor can expect a potential return of 38.63% based on the average ALNY price forecast.
Analyzing the ALNY fundamentals
Trailing Twelve Months sales for Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] were 1.83B which represents 31.25% growth. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -0.15%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.24%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is 1.67 and Total Capital is -0.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-11.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 154.08 points at the first support level, and at 152.26 for the second support level. However, for the 1st resistance point, the stock is sitting at 158.53, and for the 2nd resistance point, it is at 161.16.
Alnylam Pharmaceuticals Inc [ALNY] reported earnings per share of -$1.1 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.32/share, meaning a difference of $0.22 and a surprise factor of 16.70%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $1.15 per share as compared to estimates of -$1.34 per share, a difference of $2.49 representing a surprise of 185.80%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] is 3.08. As well, the Quick Ratio is 2.99, while the Cash Ratio is 0.84. Considering the valuation of this stock, the price to sales ratio is 10.74.
Transactions by insiders
Recent insider trading involved SHARP PHILLIP A, Director, that happened on Feb 29 ’24 when 30000.0 shares were sold. Chief Executive Officer, Greenstreet Yvonne completed a deal on Feb 28 ’24 to sell 2932.0 shares. Meanwhile, CMO & EVP Dev & Med Affairs Garg Pushkal sold 574.0 shares on Feb 28 ’24.
